ID   Adult/T315I
AC   CVCL_5K96
DR   cancercelllines; CVCL_5K96
DR   Wikidata; Q54608870
RX   PubMed=21474579;
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=21474579).
CC   Sequence variation: Mutation; HGNC; HGNC:76; ABL1; Simple; p.Thr315Ile (c.944C>T) (c.1001C>T); ClinVar=VCV000012624; Zygosity=Unspecified (PubMed=21474579).
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Adult
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 19-12-24; Version: 12
//
RX   PubMed=21474579; DOI=10.1158/1078-0432.CCR-11-0234; PMCID=PMC3096723;
RA   Nguyen T., Dai Y., Attkisson E., Kramer L., Jordan N., Nguyen N.,
RA   Kolluri N., Muschen M., Grant S.;
RT   "HDAC inhibitors potentiate the activity of the BCR/ABL kinase
RT   inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+
RT   leukemia cells in vitro and in vivo.";
RL   Clin. Cancer Res. 17:3219-3232(2011).
//